Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Persantine: Variation in Response Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00763009
Recruitment Status : Terminated (Limited numbers of patients qualified for trial)
First Posted : September 30, 2008
Results First Posted : May 24, 2017
Last Update Posted : April 13, 2018
United States Department of Defense
Information provided by (Responsible Party):
UConn Health

Brief Summary:
The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: dipyridamole Phase 4

Detailed Description:
Participants will receive three doses of Persantine intravenously for the research study. Before and after receiving the Persantine doses, patients will have an echocardiogram and coronary artery blood flow will be measured. Blood tests,measure the function of the adenosine transporter. In addition variations in the gene for the adenosine transporter will be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Persantine: Variation in Response Trial
Actual Study Start Date : September 2002
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
All subjects receive dipyridamole
Compare to baseline
Drug: dipyridamole
0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
Other Name: Persantine

Primary Outcome Measures :
  1. To Determine if There is a Subgroup of Patients That Have an Abnormal Adenosine Transporter Expression, or Abnormal Adenosine Transporter Protein Function. [ Time Frame: 6-12 months ]
    To determine if there is a subgroup of patients that have an abnormal adenosine transporter expression, or abnormal adenosine transporter protein function. All were responsive Study terminated due to difficulty enrolling

Secondary Outcome Measures :
  1. To Determine the Clinical Significance of Variations in Adenosine Transfer Function on Coronary Flow. [ Time Frame: 6-12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients > 21 years old
  • Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex

Exclusion Criteria:

  • Theophylline or oral Persantine use in 24hrs
  • Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
  • Active asthma or bronchospasm
  • Patients with severe hepatic insufficiency
  • Patients experiencing an acute transmural infarction at the time of the index visit
  • Conditions that are known to affect resistive vessel function or myocardial flow

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00763009

Layout table for location information
United States, Connecticut
UCONN Health Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
UConn Health
United States Department of Defense
Layout table for investigator information
Principal Investigator: Michael A Azrin, MD University of Connecticut
Study Chair: Bruce T Liang, MD University of Connecticut
Layout table for additonal information
Responsible Party: UConn Health Identifier: NCT00763009    
Other Study ID Numbers: 02-202-1
First Posted: September 30, 2008    Key Record Dates
Results First Posted: May 24, 2017
Last Update Posted: April 13, 2018
Last Verified: March 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents